

**Annual statistical report on substances listed in the
Convention on Psychotropic Substances of 1971**

(to be furnished to the International Narcotics Control Board (INCB) pursuant to Convention on Psychotropic Substances of 1971, articles 1, 2, 3, 12 and 16, resolution I of the United Nations Conference for the Adoption of a Protocol on Psychotropic Substances and Economic and Social Council resolutions 1576 (L), 1985/15 and 1987/30)

Country or territory: _____	Date: _____
Competent office: _____	
Name of officer responsible: _____	
Title or function: _____	Signature: _____
The statistical data relate to calendar year _____	

Remarks

**The present form can also be downloaded from INCB Home page:
<http://www.incb.org> under "Psychotropic Substances": Green List and Forms**

The Form should be completed **as soon as possible and no later than 30 June** of the year following the year to which the statistical data relate

and sent to:

International Narcotics Control Board
Vienna International Centre
P. O. Box 500, A-1400 Vienna, Austria
Telephone: + (43) (1) 26060-4277 Facsimile: + (43) (1) 26060-5867 or 26060-5868
Telegraphic address: UNATIONS VIENNA Telex: 135612 uno a
E-mail: secretariat@incb.org Home page: www.incb.org

Instructions
(to be read carefully before completing the form)

General

1. All psychotropic substances under international control are listed in the annex to the annual statistical report (“Green List”), which is distributed to Governments annually by the International Narcotics Control Board (INCB).
2. This form is divided into three parts:
 - Part one. Statistical data on the manufacture, utilization, stocks, imports and exports of substances in Schedules I, II, III and IV of the 1971 Convention and their salts;
 - Part two. Trade details: statistical data on imports and exports of substances in Schedules I, II, III and IV of the 1971 Convention;
 - Part three. Statistical data on the use of substances in Schedules I, II, III and IV of the 1971 Convention for the manufacture of other psychotropic substances.
3. In order to ensure the accurate completion of the form, it should be borne in mind that the terms used have the same meanings as those given in article 1 of the Convention on Psychotropic Substances of 1971, for example:
 - (a) “Export” and “import” mean in their respective connotations the physical transfer of a psychotropic substance from one State to another State;
 - (b) “Manufacture” means all processes by which psychotropic substances may be obtained, and includes refining as well as the transformation of psychotropic substances into other psychotropic substances. The term also includes the making of preparations other than those made on prescription in pharmacies;
 - (c) “Psychotropic substance” means any substance, natural or synthetic, or any natural material in Schedule I, II, III or IV of the Convention. The schedules are amended from time to time according to a procedure established in article 2 of the Convention;
 - (d) “Region” means any part of a State that, pursuant to article 28, is treated as a separate entity for the purposes of the Convention. The term “region” corresponds to the term “territory” used in the other statistical forms of INCB;
 - (e) “Schedule I”, “Schedule II”, “Schedule III” and “Schedule IV” mean the correspondingly numbered lists of psychotropic substances annexed to the Convention, as altered in accordance with article 2.
4. The statistical data entered on the form should be expressed in terms of the pure anhydrous base of each psychotropic substance contained in salts and preparations, excluding the weight of any non-psychotropic substance that may be combined or mixed with it. The weight should be reported in grams for psychotropic substances listed in Schedules I and II and in kilograms for substances listed in Schedules III and IV. A table of the conversion factors needed to convert quantities of psychotropic substances in salt form into quantities of pure anhydrous base content is provided in part three of the “Green List”.
5. In the case of preparations containing two or more psychotropic substances, data relating to each substance should be entered separately.

Remarks

6. In the space provided for remarks on page 1, the reporting authority may communicate to INCB any information facilitating the proper understanding of the reported statistical data. Such information may, for example, refer to a substance that was put under international control only during the year to which the report relates, in which case the reporting authority may wish to inform INCB that statistical data relating to that substance cover only the period following the date on which the inclusion of the substance in the relevant schedule of the 1971 Convention became fully effective (see article 2 of the Convention) and not the whole calendar year. Other information such as losses in the manufacturing process or seizures of psychotropic substances may also be reported under “Remarks”.

Part one. Statistical data on the manufacture, utilization, stocks, imports and exports of substances in Schedules I, II, III and IV of the 1971 Convention and their salts

Column 1 (Substance)

7. The psychotropic substances are referred to either by their international non-proprietary names (INN) or by the other non-proprietary or trivial names indicated in the schedules of the 1971 Convention. The chemical name of each psychotropic substance may also be found in the schedules or in part one of the "Green List".

Column 2 (Quantity manufactured)

8. For each psychotropic substance, the reporting authority should indicate the total quantity manufactured domestically between 1 January and 31 December of the year to which the statistical data relate. The quantities of psychotropic substances used for the preparation of pharmaceutical dosage forms should be indicated under column 6 (Imports) and should not be included under column 2 (Quantity manufactured).

Column 3 (Quantity used for the manufacture of non-psychotropic substances or products)

9. For each psychotropic substance listed in Schedules II, III and IV, the reporting authority should indicate the quantity used for the manufacture of non-psychotropic substances or products (permitted under article 4, paragraph (b), of the 1971 Convention). That quantity should include the total amount placed in the manufacturing process during the year to which the statistical data relate, even if the manufacturing process was not completed by the end of that year. Not applicable for substances in Schedule I.

Column 4 (Quantity used for the manufacture of preparations exempted under article 3, paragraphs 2 and 3)

10. For each psychotropic substance listed in Schedules II and III, the reporting authority should indicate the total quantity used for manufacture of preparations exempted from certain measures of control (permitted under article 3, paragraphs 2 and 3, of the 1971 Convention). That quantity should include the total amount placed in the manufacturing process during the year to which the statistical data relate, even if the manufacturing process was not completed by the end of that year. The quantities reported with respect to substances in Schedule II should be expressed in grams and those reported with respect to substances in Schedule III in kilograms. Figures for psychotropic substances in Schedule IV may also be reported (in kilograms). Not applicable for substances in Schedule I.

Column 5 (Manufacturers' stocks as at 31 December)

11. For each psychotropic substance listed in Schedules I and II, the reporting authority should indicate (in grams) the quantity held in stock by manufacturers on 31 December of the year to which the statistical data relate. Figures for psychotropic substances in Schedules III and IV may also be reported (in kilograms).

Columns 6 (Imports) and 7 (Exports)

12. Statistical data should be based, to the extent possible, on actual movements across borders.

13. For each psychotropic substance listed in Schedules I and II, the reporting authority should indicate (in grams) the total quantity imported in column 6 and the total quantity exported in column 7; these quantities must be detailed by country or region of origin in section V and by country or region of destination in section VI.

14. For each psychotropic substance listed in Schedules III and IV, the reporting authority should indicate (in kilograms) the total quantity imported in column 6 and the total quantity exported in column 7. Pursuant to Economic and Social Council resolution 1985/15 of 28 May 1985, the quantities reported in column 6 may be detailed by country or region of origin in section VII, entitled "Trade details: import of substances in Schedules III and IV, by country or region of origin", and the quantities reported in column 7 may be detailed by country or region of destination in section VIII, entitled "Trade details: export of substances in Schedules III and IV, by country or region of destination".

Part two. Trade details: statistical data on imports and exports of substances in Schedules I, II, III and IV of the 1971 Convention

15. The term “import”, as used in the 1971 Convention, is intended to include, as far as possible, the entrance of goods from abroad into a bonded warehouse, free port or free zone; similarly, the term “export” is intended to include the dispatch of goods abroad from a bonded warehouse, free port or free zone, although such transactions may not be treated by the national customs laws as imports and exports. However, care should be taken to ensure that goods passing through customs from a bonded warehouse, free port or free zone into the country or region itself are not recorded as imports, and that goods transferred from the country or region itself into a bonded warehouse, free port or free zone situated in the country or region are not recorded as exports. However, if a consignment passes in transit through a country or region to another country, it should not be considered by the country or region through which it passes as an import and subsequent export, even if the consignment is placed temporarily in a bonded warehouse, free port or free zone.

16. Goods returned by a country or region, for any reason whatsoever, to the original exporting country or region shall be entered as an export by the former and as an import by the latter.

17. In section V, entitled “Trade details: import of substances in Schedules I and II, by country or region of origin”, for each substance listed in Schedules I and II, indicate the name of the substance, the total quantity imported as reported in column 6 (in grams) in sections I and II and, under “Imported from”, the name of the exporting country or region.

18. In section VI, entitled “Trade details: export of substances in Schedules I and II, by country or region of destination”, for each of the substances reported in Schedules I and II, indicate the name of the substance, the total quantity exported as reported in column 7 (in grams) in sections I and II and, under “Exported to”, the name of the importing country or region.

19. In section VII, entitled “Trade details: import of substances in Schedules III and IV, by country or region of origin”, for each substance listed in Schedules III and IV, the quantities reported in column 6 in sections III and IV may be detailed by country or region of origin. In section VIII, entitled “Trade details: export of substances in Schedules III and IV, by country or region of destination”, for each substance listed in Schedules III and IV, the quantities reported in column 7 in sections III and IV may be detailed by country or region of destination.

Part three. Statistical data on the use of substances in Schedules I, II, III and IV of the 1971 Convention for the manufacture of other psychotropic substances

20. Countries and territories are requested to provide information, on a voluntary basis, on the use of psychotropic substances listed in Schedules I, II, III and IV for the manufacture of other psychotropic substances, indicating the name of the source substance, the quantity used in the manufacturing process, the name of the other psychotropic substance derived from the manufacturing process and the quantity of that substance derived from the manufacturing process.

Part one. Statistical data on the manufacture, utilization, stocks, imports and exports of substances in Schedules I, II, III and IV of the 1971 Convention and/or their salts

I. Statistical data on substances in Schedule I and/or their salts (Grams)

	<i>1</i>	<i>2</i>	<i>3</i>	<i>4</i>	<i>5</i>	<i>6</i>	<i>7</i>
	<i>Substance</i>	<i>Quantity manufactured</i>	<i>Quantity used for the manufacture of non-psychootropic substances or products</i>	<i>Quantity used for the manufacture of preparations exempted under article 3, paragraphs 2 and 3</i>	<i>Manufacturers' stocks as at 31 December</i>	<i>Total imports (these quantities must be detailed by country or region of origin in section V)</i>	<i>Total exports (these quantities must be detailed by country or region of destination in section VI)</i>
PD 009	Brolamfetamine (DOB)		(Not applicable)				
PC 010	Cathinone						
PD 001	DET						
PD 007	DMA						
PD 003	DMHP						
PD 004	DMT						
PD 008	DOET						
PP 003	Eticyclidine (PCE)						
PE 006	Etryptamine						
PL 002	(+)-Lysergide (LSD or LSD-25)						
PM 011	MDMA						
PM 004	Mescaline						
PM 019	Methcathinone						
PM 017	4-methylaminorex						
PM 020	4-MTA						
PM 013	MMDA						
PN 004	N-ethyl-MDA (MDEA)						
PN 005	N-hydroxy-MDA						
PP 001	Parahexyl						
PP 017	PMA						
PP 012	Psilocine or psilotsin						
PP 013	Psilocybine						
PP 007	Rolicyclidine (PHP or PCPY)						
PS 002	STP or DOM						

	1	2	3	4	5	6	7
	<i>Substance</i>	<i>Quantity manufactured</i>	<i>Quantity used for the manufacture of non-psychoactive substances or products</i>	<i>Quantity used for the manufacture of preparations exempted under article 3, paragraphs 2 and 3</i>	<i>Manufacturers' stocks as at 31 December</i>	<i>Total imports (these quantities must be detailed by country or region of origin in section V)</i>	<i>Total exports (these quantities must be detailed by country or region of destination in section VI)</i>
PM 014	Tenamfetamine (MDA)						
PT 001	Tenocyclidine (TCP)						
PT 002	Tetrahydrocannabinol, the following isomers and their stereochemical variants: $\Delta^{6a(10a)}$, $\Delta^{6a(7)}$, Δ^7 , Δ^8 , Δ^{10} and $\Delta^{9(11)}$						
PT 006	TMA						

II. Statistical data on substances in Schedule II and/or their salts (Grams)

	1	2	3	4	5	6	7
	<i>Substance</i>	<i>Quantity manufactured</i>	<i>Quantity used for the manufacture of non-psychoactive substances or products</i>	<i>Quantity used for the manufacture of preparations exempted under article 3, paragraphs 2 and 3</i>	<i>Manufacturers' stocks as at 31 December</i>	<i>Total imports (these quantities must be detailed by country or region of origin in section V)</i>	<i>Total exports (these quantities must be detailed by country or region of destination in section VI)</i>
PA 003	Amfetamine						
PA 007	Amineptine						
PB 008	2C-B						
PD 002	Dexamfetamine						
PF 005	Fenetylline						
PL 006	Levamphetamine						
PL 007	Levomethamphetamine						
PM 002	Mecloqualone						
PM 005	Metamphetamine						
PM 015	Metamphetamine racemate						
PM 006	Methaqualone						
PM 007	Methylphenidate						
PP 005	Phencyclidine (PCP)						

	1	2	3	4	5	6	7
	<i>Substance</i>	<i>Quantity manufactured</i>	<i>Quantity used for the manufacture of non-psychoactive substances or products</i>	<i>Quantity used for the manufacture of preparations exempted under article 3, paragraphs 2 and 3</i>	<i>Manufacturers' stocks as at 31 December</i>	<i>Total imports (these quantities must be detailed by country or region of origin in section V)</i>	<i>Total exports (these quantities must be detailed by country or region of destination in section VI)</i>
PP 006	Phenmetrazine						
PS 001	Secobarbital						
PD 010	* <i>Delta-9-THC</i>						
PZ 001	Zipeprol						

* This refers to *delta-9-tetrahydrocannabinol* and its stereochemical variants from synthetic origin. Information on *delta-9-tetrahydrocannabinol* originating from the cannabis plant (Indian hemp) should be reported as a narcotic drug in Form C (Annual Statistics of production, manufacture, consumption, stocks and seizures of narcotic drugs) in terms of cannabis resin or cannabis extract.

III. Statistical data on substances in Schedule III and/or their salts (Kilograms)

	1	2	3	4	5	6	7
	<i>Substance</i>	<i>Quantity manufactured</i>	<i>Quantity used for the manufacture of non-psychoactive substances or products</i>	<i>Quantity used for the manufacture of preparations exempted under article 3, paragraphs 2 and 3</i>	<i>Manufacturers' stocks as at 31 December (voluntary)</i>	<i>Total imports</i>	<i>Total exports</i>
PA 002	Amobarbital						
PB 006	Buprenorphine						
PB 004	Butalbital						
PC 009	Cathine						
PC 001	Cyclobarbital						
PF 002	Flunitrazepam						
PG 001	Glutethimide						
PP 014	Pentazocine						
PP 002	Pentobarbital						

IV. Statistical data on substances in Schedule IV and/or their salts
(Kilograms)

	<i>1</i>	<i>2</i>	<i>3</i>	<i>4</i>	<i>5</i>	<i>6</i>	<i>7</i>
	<i>Substance</i>	<i>Quantity manufactured</i>	<i>Quantity used for the manufacture of non-psychoactive substances or products</i>	<i>Quantity used for the manufacture of preparations exempted under article 3, paragraphs 2 and 3 (voluntary)</i>	<i>Manufacturers' stocks as at 31 December (voluntary)</i>	<i>Total imports</i>	<i>Total exports</i>
PA 005	Allobarbitol						
PA 004	Alprazolam						
PA 001	Amfepramone						
PA 006	Aminorex						
PB 001	Barbital						
PB 002	Benzfetamine						
PB 003	Bromazepam						
PB 007	Brotizolam						
PB 005	Butobarbital						
PC 002	Camazepam						
PC 003	Chlordiazepoxide						
PC 004	Clobazam						
PC 005	Clonazepam						
PC 006	Clorazepate						
PC 007	Clotiazepam						
PC 008	Cloxazolam						
PD 005	Delorazepam						
PD 006	Diazepam						
PE 003	Estazolam						
PE 001	Ethchlorvynol						
PE 002	Ethinamate						
PE 004	Ethyl loflazepate						
PE 005	Etilamfetamine						
PF 004	Fencamfamin						
PF 006	Fenproporex						
PF 001	Fludiazepam						
PF 003	Flurazepam						

	<i>1</i>	<i>2</i>	<i>3</i>	<i>4</i>	<i>5</i>	<i>6</i>	<i>7</i>
	<i>Substance</i>	<i>Quantity manufactured</i>	<i>Quantity used for the manufacture of non-psychoactive substances or products</i>	<i>Quantity used for the manufacture of preparations exempted under article 3, paragraphs 2 and 3 (voluntary)</i>	<i>Manufacturers' stocks as at 31 December (voluntary)</i>	<i>Total imports</i>	<i>Total exports</i>
PG 002	GHB						
PH 001	Halazepam						
PH 002	Haloxazolam						
PK 001	Ketazolam						
PL 001	Lefetamine (SPA)						
PL 003	Loprazolam						
PL 004	Lorazepam						
PL 005	Lormetazepam						
PM 001	Mazindol						
PM 010	Medazepam						
PM 012	Mefenorex						
PM 003	Meprobamate						
PM 018	Mesocarb						
PM 008	Methylphenobarbital						
PM 009	Methyprylon						
PM 016	Midazolam						
PN 001	Nimetazepam						
PN 002	Nitrazepam						
PN 003	Nordazepam						
PO 001	Oxazepam						
PO 002	Oxazolam						
PP 020	Pemoline						
PP 004	Phendimetrazine						
PP 008	Phenobarbital						
PP 009	Phentermine						
PP 015	Pinazepam						
PP 010	Pipradrol						
PP 016	Prazepam						
PP 019	Pyrovalerone						

	<i>1</i>	<i>2</i>	<i>3</i>	<i>4</i>	<i>5</i>	<i>6</i>	<i>7</i>
	<i>Substance</i>	<i>Quantity manufactured</i>	<i>Quantity used for the manufacture of non-psychootropic substances or products</i>	<i>Quantity used for the manufacture of preparations exempted under article 3, paragraphs 2 and 3 (voluntary)</i>	<i>Manufacturers' stocks as at 31 December (voluntary)</i>	<i>Total imports</i>	<i>Total exports</i>
PS 003	Secbutabarbital						
PT 003	Temazepam						
PT 004	Tetrazepam						
PT 005	Triazolam						
PV 001	Vinylbital						
PZ 002	Zolpidem						

